SR-9009 (Stenabolic) – Metabolism and Biological Clock Research

It’s 3 a.m. Your brain produces melatonin, your intestines slow down your peristalsis, your body temperature drops to a minimum. Every cell in the body “knows” that it is night – and behaves accordingly. This internal schedule is the biological clock: a network of feedbacks between clock genes that synchronizes metabolism, immunity, regeneration and sleep with the day-night cycle. What if there was a compound that influenced the very mechanism of this clock – reprogramming the cells’ metabolic “hour” regardless of the time of day? This is exactly what the SR-9009 tries to achieve.

📖 The following article is educational and is a review of published scientific literature. The studies described were performed in animal models or in vitro, unless otherwise noted. This does not constitute medical advice.

What is SR-9009 and how was it created

SR-9009 (Stenabolic) is a synthetic agonist of the Rev-Erbα protein – one of the elements of the molecular biological clock. Developed by the team of prof. Thomas Burris from Scripps Research Institute (La Jolla, California) as a research tool for exploring the function of Rev-Erbα in the regulation of metabolism.

Important distinction: SR-9009 it is not a SARM. It does not bind to the androgen receptor. It is also not a PPARδ agonist like Cardarin (GW-501516). This is a class of its own – an agonist of the nuclear receptor Rev-Erbα, a protein that acts as a link between the biological clock and cellular metabolism.

SR-9009 is sometimes grouped with SARMs and metabolic modulators in research reagent stores. Pharmacologically, however, it is a tool with a unique mechanism – influencing the expression of metabolic genes by modulating the circadian rhythm.

You can find more about the context of SARMs and modulators in the overview article SARMs – what they are, how they work and what the science says on selective androgen receptor modulators.

Mechanism of action — Rev-Erbα and the biological clock

Clock genes – the body’s internal schedule

Each cell in the body has its own “clock” – a feedback loop between clock genes (CLOCK, BMAL1, PER, CRY, Rev-Erbα, Rev-Erbβ, ROR). These genes turn each other’s expression on and off on a roughly 24-hour cycle, creating an oscillation that synchronizes metabolism with the day-night cycle.

Rev-Erbα is one of the brakes in this loop. When Rev-Erbα levels increase (peak during active hours), this protein turns off the expression of BMAL1 – one of the main clock activators. When Rev-Erbα declines (night), BMAL1 resumes activity. This cyclical dance generates a circadian rhythm.

What does Rev-Erbα do outside of the clock?

Rev-Erbα doesn’t stop at ticking the clock. It also regulates the expression of metabolic genes – especially those responsible for:

• Lipid metabolism — fatty acid utilization and cholesterol synthesis
• Mitochondria biogenesis — production of new mitochondria in muscle cells
• Autophagy — “recycling” of damaged cell organelles
• Inflammatory response — modulation of the expression of pro-inflammatory cytokines
• Hepatic gluconeogenesis — glucose production in the liver

SR-9009 activates Rev-Erbα – enhancing its inhibitory effects on target genes. The effect: the cell “thinks” that Rev-Erbα is at the peak of its cycle (day/activity) – and adjusts its metabolism accordingly.

Analogy: Imagine a thermostat that controls the heating in your home. Normally, the thermostat adjusts itself automatically – warmer in the morning, cooler at night. SR-9009 is like setting the thermostat permanently “in the morning”: the metabolism works in daily mode regardless of the actual time.

Effects on metabolism in preclinical studies

Solt et al. (2012) – original study from Scripps

A groundbreaking publication in Nature (2012) was the starting point for interest in SR-9009. Burris’ team showed that mice treated with SR-9009:

• They lost fat mass despite a diet without calorie restrictions
• They showed reduced plasma triglyceride levels
• They had lower total cholesterol levels
• They showed reduced fasting glucose levels
• Increased running efficiency by approximately 50%

The study by Solt et al. (2012) was performed in a mouse model. All metabolic and performance results are for mice, not humans. There are no human clinical trials of SR-9009.

Importantly: metabolic effects were observed both in healthy mice and in mice with an obesity-inducing diet. SR-9009 “protected” against fat gain even in excess calories—suggesting that the effect is not due to appetite reduction but rather to reprogramming energy metabolism.

Woldt et al. (2013) – mitochondria and skeletal muscle

Study published in Nature Medicine showed that Rev-Erbα directly regulates mitochondrial biogenesis in skeletal muscle. Mice with the Rev-Erbα gene deleted (knockout) had fewer mitochondria, lower efficiency and worse ability to utilize fatty acids.

Activation of Rev-Erbα by SR-9009 caused the opposite effect: more mitochondria, better fatty acid oxidation, higher efficiency. This is a mechanistic explanation for the effects observed by Solt – more mitochondria = more fat-burning “power plants” = less body fat.

The study by Woldt et al. (2013) were performed in knockout and pharmacological mouse models. The translation of the results to human physiology has not been confirmed.

Effects on inflammatory markers

A separate line of research has shown that SR-9009 modulates the inflammatory response – lowering the expression of IL-6, TNF-α and other pro-inflammatory cytokines in macrophages. This effect is consistent with the function of Rev-Erbα as a regulator of inflammatory genes and may explain some of the observed metabolic effects (chronic inflammation is accompanied by obesity and insulin resistance).

Are you conducting research on chronobiology, mitochondrial metabolism or Rev-Erbα function? Check SR-9009 One-Peptides research reagents offer – with analytical documentation and HPLC certificate for each batch.

SR-9009 and circadian rhythm – the clock that affects everything

SR-9009’s function as a biological clock modulator opens intriguing research questions that go far beyond fat metabolism.

Circadian rhythm disturbances (shift work, jet lag, chronic disruption of the sleep-wake cycle) correlate with an increased risk of obesity, type 2 diabetes, cardiovascular diseases and mood disorders. Mechanism? Desynchronization of peripheral clocks (in liver cells, muscles, adipose tissue) with the central clock in the suprachiasmatic nucleus (SCN) of the hypothalamus.

SR-9009, by affecting Rev-Erbα in peripheral tissues, could theoretically “resynchronize” cellular metabolism independently of signals from the central clock. This is a research hypothesis, not a proven application – but a direction of scientific exploration that is generating significant interest in the field of chronobiology.

The metabolism-sleep-inflammation triangle:

• Disturbed sleep → desynchronization of peripheral clocks → deteriorated lipid metabolism
• Worsened metabolism → fat accumulation → chronic low-grade inflammation
• Inflammation → disruption of clock signaling → further deterioration of sleep

SR-9009, by influencing the clock element of this triangle, could theoretically break this vicious circle. An elegant theory – but still a theory based solely on data from animal models.

Problem with oral bioavailability

This is the section that an honest article about SR-9009 must include — and one that distinguishes sound education from a marketing narrative.

SR-9009 has notorious problems with oral bioavailability. Pharmacokinetic studies (conducted on a mouse model) showed that after oral administration, only approximately 2% of the compound reaches the systemic circulation in an active form. The rest undergoes the first-pass effect in the liver – it is metabolized before it can reach target tissues.

In Solt and team’s original study, SR-9009 was administered intraperitoneally (intra-abdominal injection) to mice – which bypasses the liver and provides significantly higher bioavailability. The metabolic effects observed in these studies do not necessarily translate to oral administration.

This is a pharmacological limitation, not a marketing defect. There are attempts to improve bioavailability: liposomal, subcutaneous, sublingual forms – but none have been validated in rigorous studies.

For researchers: low oral bioavailability means that in vivo experiments with SR-9009 require careful selection of the route of administration and dosage. Extrapolation of doses between routes of administration is complex and requires consideration of pharmacokinetics.

SR-9009 vs Cardarine (GW-501516) – different mechanisms, similar goals

Both molecules end up in the “metabolic” basket of research reagents – but they affect metabolism from completely different sides. Cardarine flips the “fuel switch” in cells. SR-9009 affects the clock itself, which determines when and how the cell metabolizes energy.

A detailed discussion of Cardarine can be found in the article Cardarine – what is it and what does it do?.

Are you comparing metabolic reagents to your research? At One-Peptides you will find both SR-9009 and GW-501516 – both HPLC certified for identity and purity.

FAQ – Frequently asked questions

Summary

• SR-9009 (Stenabolic) is an agonist of Rev-Erbα – a protein that acts as a link between the biological clock and cellular metabolism
• It is not a SARM or a PPARδ agonist – it is a separate pharmacological class
• Studies on mice (Solt et al., 2012) showed a reduction in body fat, an improvement in the lipid profile and an increase in running performance by ~50%
• Mechanism: mitochondrial biogenesis, increased fatty acid oxidation, modulation of inflammatory genes
• Major limitation: very low oral bioavailability (~2% in mice)
• There are no clinical trials in humans – the entire evidence base is based on animal models
• A potentially interesting research direction in chronobiology and metabolism – but at an early stage of development
• Banned by WADA as a metabolic modulator

ℹ️ Global disclaimer

All One-Peptides products are reagents intended exclusively for laboratory and scientific research (Research Use Only). They are not medicines, dietary supplements or products intended for human consumption. The information in this article is educational in nature and is a review of published scientific literature; does not constitute medical, pharmaceutical or dietary advice. SR-9009 is on the WADA Prohibited Substances List.

Bartosz BartczakPhysiotherapist, Personal Trainer

Physiotherapist with 20 years of clinical experience, graduate of Poznan University of Medical Sciences. Founder of One Peptides and lead author of clinical-perspective content.

See Full Bio ›